No Data
Stifel Maintains GH Research(GHRS.US) With Buy Rating
Optimistic Outlook for GH Research: Promising Phase 2a Results and Favorable Safety Profile
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
JMP Securities Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $39
Promising Advancements and Strong Financial Position Bolster Buy Rating for GH Research
GH Research Says Its Two Phase 2 POC Studies Of GH001 Met Primary Goals; Stock Up In Pre-Market